Omada Health is trading at $19.30, up 5.49% in pre-market on October 14, with no clear company-specific catalyst identified. - Shares fell 16.32% in the regular session on October 13. - Omada Health’s November 5 Q3 results notice was a scheduled-event announcement, not an earnings release. A report noted a Wall Street Zen rating upgrade, but available reporting does not establish it as the reason for the move. - Major indices were only modestly higher, offering no clear broad-market explanation.